Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125335 | 1.00 | HTT (0.43) | HTTALDH1A1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1758234 | 1.00 | HTT (0.43) | HTTALDH1A1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL3771814 | 0.80 | AKR1C3 (0.47) | AKR1C3AKR1C2AKR1C1KMT2AMEN1 | |
| SCHEMBL2851432 | 0.80 | AKR1C3 (0.47) | AKR1C3AKR1C2AKR1C1KMT2AMEN1 | |
| SCHEMBL1758388 | 0.79 | AKR1C3 (0.42) | HTTALDH1A1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1758384 | 0.79 | AKR1C3 (0.42) | HTTALDH1A1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL4455663 | 0.79 | AKR1C3 (0.42) | HTTALDH1A1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7880140 | 0.76 | ABL1 (0.42) | ALDH1A1AKR1C3KMT2AKDM4EPOLB | |
| SCHEMBL7880143 | 0.76 | ABL1 (0.42) | ALDH1A1AKR1C3KMT2AKDM4EPOLB | |
| SCHEMBL3822843 | 0.73 | GABRA1 (0.47) | HTTALDH1A1KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954683-B1 | 2-(PHENYL OR HETEROCYCLYL)-1H-PHENANTHRO(9,10-D)IMIDAZOLES AS MPGES-1 INHIBITORS | MERCK CANADA INC (CA) | 2016-03-02 | — | — | EP | disclosed |
| EP-1828143-B1 | 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2013-03-20 | — | — | EP | disclosed |
| US-7943649-B2 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2011-05-17 | — | — | US | disclosed |
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | MERCK FROSST CANADA LTD. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090111997-A1 | Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals | MERCK SHARP & DOHME CORP. | 2009-04-30 | — | — | US | disclosed |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2009-03-19 | — | — | US | disclosed |
| EP-2019675-A1 | METHODS FOR TREATING OR PREVENTING NEOPLASIAS | Merck Frosst Canada Ltd. (CA) | 2009-02-04 | — | — | EP | disclosed |
| US-7442716-B2 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2008-10-28 | — | — | US | disclosed |
| WO-2007124589-A1 | METHODS FOR TREATING OR PREVENTING NEOPLASIAS | MERCK FROSST CANADA LTD. (CA) | 2007-11-08 | — | — | WO | disclosed |
| US-20070208017-A1 | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | GSTO1, PTGS1, PTGES | HTT 3029/4885ALDH1A1 78/4885AKR1C3 93/4885 |
| US-20070208017-A1 | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | HTT 2987/4885ALDH1A1 165/4885AKR1C3 282/4885 |
| US-20090111997-A1 | Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals | WDR33, POLR2H, NSF | HTT 110/4885ALDH1A1 3974/4885AKR1C3 3586/4885 |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | HTT 2987/4885ALDH1A1 165/4885AKR1C3 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.